These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 15356811)

  • 1. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
    van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
    Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
    McNeill L; Allen M; Estrada C; Cook P
    Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
    Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
    Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
    Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics.
    Lee AM; Mennone JZ; Jones RC; Paul WS
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):995-1000. PubMed ID: 12475146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
    Stout JE
    Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity.
    Kunimoto D; Warman A; Beckon A; Doering D; Melenka L
    Clin Infect Dis; 2003 Jun; 36(12):e158-61. PubMed ID: 12802781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
    Gordin FM; Cohn DL; Matts JP; Chaisson RE; O'Brien RJ; ; ;
    Clin Infect Dis; 2004 Aug; 39(4):561-5. PubMed ID: 15356822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?
    Nader LA; de Mattos AA; Picon PD; Bassanesi SL; De Mattos AZ; Pineiro Rodriguez M
    Ann Hepatol; 2010; 9(1):70-4. PubMed ID: 20308724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
    Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
    JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.
    Cook PP; Maldonado RA; Yarnell CT; Holbert D
    Clin Infect Dis; 2006 Aug; 43(3):271-5. PubMed ID: 16804838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
    McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR
    Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide.
    Lin HS; Cheng CW; Lin MS; Chou YL; Chang PJ; Lin JC; Ye JJ
    Clin Interv Aging; 2016; 11():299-306. PubMed ID: 27042029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
    Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE
    Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
    Duarte R; Carvalho A; Correia A
    Public Health; 2012 Sep; 126(9):760-2. PubMed ID: 22633080
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis.
    Stout JE; Engemann JJ; Cheng AC; Fortenberry ER; Hamilton CD
    Am J Respir Crit Care Med; 2003 Mar; 167(6):824-7. PubMed ID: 12446275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
    Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
    Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antituberculosis drugs and hepatotoxicity.
    Yew WW; Leung CC
    Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.